NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $2.17 -0.01 (-0.46%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$2.10▼$2.2050-Day Range$1.85▼$2.6352-Week Range$1.51▼$2.97Volume697,300 shsAverage Volume1.38 million shsMarket Capitalization$376.19 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Erasca alerts: Email Address Erasca MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside176.5% Upside$6.00 Price TargetShort InterestBearish9.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$181,600 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.77) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.00 out of 5 starsMedical Sector532nd out of 879 stocksPharmaceutical Preparations Industry248th out of 417 stocks 3.4 Analyst's Opinion Consensus RatingErasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 2 research reports in the past 90 days.Read more about Erasca's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.20% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Erasca has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next N/A News and Social Media Coverage Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have bought more of their company's stock than they have sold. Specifically, they have bought $181,600.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to decrease in the coming year, from ($0.77) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Erasca's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Erasca Stock (NASDAQ:ERAS)Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More ERAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERAS Stock News HeadlinesMay 29, 2024 | globenewswire.comErasca to Present at Upcoming Investor Conferences in JuneMay 23, 2024 | finance.yahoo.comIndependent Director of Erasca Picks Up 14% More StockJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.May 21, 2024 | finance.yahoo.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesMay 21, 2024 | globenewswire.comErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesMay 20, 2024 | markets.businessinsider.comErasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline PositioningMay 20, 2024 | markets.businessinsider.comOptimistic Outlook for Erasca: Strategic Growth and Financial PrudenceMay 17, 2024 | msn.comErasca stock climbs 10% amid pipeline restructuring, equity offeringJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.May 16, 2024 | globenewswire.comErasca Announces Strategic In-Licensing of RAS-Targeting FranchiseMay 16, 2024 | globenewswire.comErasca Announces Pricing of Underwritten Offering of Common StockMay 14, 2024 | markets.businessinsider.comErasca’s Stable Cash Runway and Upcoming Clinical Milestones Secure Buy RatingMay 9, 2024 | investorplace.comERAS Stock Earnings: Erasca Misses EPS for Q1 2024May 8, 2024 | globenewswire.comErasca Reports First Quarter 2024 Business Updates and Financial ResultsMay 7, 2024 | finance.yahoo.comErasca to Present at the Bank of America Health Care ConferenceApril 24, 2024 | globenewswire.comErasca Announces Three Presentations at the 2024 ASCO Annual MeetingApril 16, 2024 | finance.yahoo.comInstitutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year lossesApril 9, 2024 | fool.comErasca (NASDAQ: ERAS)See More Headlines Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+176.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.83% Return on Assets-31.22% Debt Debt-to-Equity RatioN/A Current Ratio10.14 Quick Ratio10.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book1.03Miscellaneous Outstanding Shares173,360,000Free Float136,087,000Market Cap$376.19 million OptionableOptionable Beta1.16 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jonathan E. Lim M.D. (Age 52)Co-Founder, Chairman & CEO Comp: $940.32kDr. David M. Chacko M.D. (Age 40)CFO & Chief Business Officer Comp: $616.76kDr. Michael D. Varney Ph.D. (Age 66)Chairman of Research & Development, Scientific Advisory Board Member and Director Comp: $83.26kDr. Nik Chetwyn Ph.D.Chief Operating OfficerMr. Ebun S. Garner J.D. (Age 52)Esq., General Counsel & Corporate Secretary Comp: $510.98kDr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 57)M.S., Senior Vice President of Finance Ms. Chandra D. Lovejoy M.S. (Age 53)Chief Regulatory Affairs Officer Dr. Robert Shoemaker Ph.D. (Age 43)Senior Vice President of Research Dr. Shannon R. Morris M.D. (Age 54)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELVerve TherapeuticsNASDAQ:VERVBlack Diamond TherapeuticsNASDAQ:BDTXRelay TherapeuticsNASDAQ:RLAYAkero TherapeuticsNASDAQ:AKROView All CompetitorsInsiders & InstitutionsAlexander W CasdinBought 80,000 shares on 5/21/2024Total: $181,600.00 ($2.27/share)EntryPoint Capital LLCSold 48,459 shares on 5/14/2024Ownership: 0.019%Vanguard Group Inc.Bought 545,765 shares on 5/10/2024Ownership: 2.502%Acadian Asset Management LLCBought 257,174 shares on 5/10/2024Ownership: 0.200%Susquehanna Fundamental Investments LLCBought 104,691 shares on 5/7/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.13 at the beginning of 2024. Since then, ERAS stock has increased by 1.9% and is now trading at $2.17. View the best growth stocks for 2024 here. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.02. When did Erasca IPO? Erasca (ERAS) raised $262 million in an IPO on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ERAS) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.